8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 18, 2026·SEC
4D Molecular Therapeutics, Inc.(FDMT)Earnings, Financials & Key Ratios
FDMT•NASDAQ
Price updated Jun 19, 2026
About4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.Show more
- Revenue$85M+230194.6%
- EBITDA-$152M+16.1%
- Net Income-$140M+12.9%
- EPS (Diluted)-2.42+18.8%
- Gross Margin91.05%-8.9%
- EBITDA Margin-178.29%+100.0%
- Operating Margin-187.24%+100.0%
- Net Margin-164.43%+100.0%
- ROE-27.57%+29.9%
FDMT Key Insights
4D Molecular Therapeutics, Inc. (FDMT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 44.3%
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Profits declining 19.8% over 5 years
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when FDMT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FDMT Price & Volume
4D Molecular Therapeutics, Inc. (FDMT) stock price & volume — 10-year historical chart
Loading chart...
FDMT Growth Metrics
4D Molecular Therapeutics, Inc. (FDMT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years44.32%
3 Years200.86%
TTM383560.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM8.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM16.35%
Return on Capital
10 Years-39.81%
5 Years-35.07%
3 Years-38.06%
Last Year-30.28%
FDMT Recent Earnings
4D Molecular Therapeutics, Inc. (FDMT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.01-4.1%
$0.97
Rev
$3M+17.8%
$3M
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.43+181.1%
$0.53
Rev
$85M+215.2%
$27M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$1.01+1.0%
$1.02
Rev
$90,000-99.7%
$31M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.98-11.4%
$0.88
Rev
$15,000+221.2%
$4,670
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.01vs $0.97-4.1% | $3Mvs $3M+17.8% |
| Q2 2026 | Mar 18, 2026 | $0.43vs $0.53+181.1% | $85Mvs $27M+215.2% |
| Q4 2025 | Nov 10, 2025 | $1.01vs $1.02+1.0% | $90,000vs $31M-99.7% |
| Q3 2025 | Aug 11, 2025 | $0.98vs $0.88-11.4% | $15,000vs $4,670+221.2% |
Based on last 12 quarters of dataView full earnings history →
FDMT Peer Comparison
4D Molecular Therapeutics, Inc. (FDMT) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OCGN | 419.77M | 1.24 | -5.39 | 8.83% | -16.05% | -1279.88% | ||
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 QURE | 2.89B | 46.29 | -13.38 | -40.64% | -11.54% | -145.81% | 2.70 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 |
Compare FDMT vs Peers
4D Molecular Therapeutics, Inc. (FDMT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FDMT Income Statement
4D Molecular Therapeutics, Inc. (FDMT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 5.79M | 14.13M | 6.99M | 13.61M | 18.04M | 3.13M | 20.72M | 37K | 85.21M | 88.24M |
Revenue Growth % | - | 144.04% | -50.56% | 94.85% | 32.52% | -82.65% | 562.29% | -99.82% | 230194.59% | 383560.87% |
Cost of Goods Sold | 13.57M | 18.36M | 38.72M | 53.04M | 61.36M | 80.25M | 97.1M | 0 | 7.63M | 99.22M |
COGS % of Revenue | 234.42% | 129.95% | 554.22% | 389.64% | 340.17% | 2564.81% | 468.54% | - | 8.95% | - |
Gross Profit | -7.78M▲ 0% | -4.23M▲ 45.6% | -31.73M▼ 649.8% | -39.43M▼ 24.2% | -43.32M▼ 9.9% | -77.12M▼ 78.0% | -76.37M▲ 1.0% | 37K▲ 100.0% | 77.58M▲ 209586.5% | -10.98M▲ 0% |
Gross Margin % | -134.42% | -29.95% | -454.22% | -289.64% | -240.17% | -2464.81% | -368.54% | 100% | 91.05% | -12.45% |
Gross Profit Growth % | - | 45.63% | -649.81% | -24.25% | -9.88% | -78.03% | 0.97% | 100.05% | 209586.49% | - |
Operating Expenses | 17.06M | 24.53M | 19.03M | 17.24M | 28.01M | 32.91M | 36.49M | 187.88M | 237.13M | 168.56M |
OpEx % of Revenue | 294.68% | 173.6% | 272.43% | 126.64% | 155.29% | 1051.71% | 176.1% | 507778.38% | 278.29% | - |
Selling, General & Admin | 3.49M | 6.17M | 13.89M | 17.24M | 28.01M | 32.91M | 36.49M | 46.58M | 49.06M | 47.81M |
SG&A % of Revenue | 60.26% | 43.64% | 198.9% | 126.64% | 155.29% | 1051.71% | 176.1% | 125889.19% | 57.58% | - |
Research & Development | 13.57M | 18.36M | 43.85M | 53.04M | 61.36M | 80.25M | 97.1M | 141.3M | 195.7M | 219.98M |
R&D % of Revenue | 234.42% | 129.95% | 627.76% | 389.64% | 340.17% | 2564.81% | 468.54% | 381889.19% | 229.67% | - |
Other Operating Expenses | -40K | -2K | -38.72M | -53.04M | -61.36M | -80.25M | -97.1M | 0 | -7.63M | -4M |
Operating Income | -11.27M▲ 0% | -10.4M▲ 7.7% | -50.76M▼ 388.2% | -56.66M▼ 11.6% | -71.33M▼ 25.9% | -110.03M▼ 54.3% | -112.87M▼ 2.6% | -187.84M▼ 66.4% | -159.55M▲ 15.1% | -179.55M▲ 0% |
Operating Margin % | -194.68% | -73.6% | -726.65% | -416.28% | -395.46% | -3516.52% | -544.65% | -507678.38% | -187.24% | -203.47% |
Operating Income Growth % | - | 7.74% | -388.16% | -11.62% | -25.89% | -54.25% | -2.58% | -66.43% | 15.06% | - |
EBITDA | -10.65M | -9.7M | -49.76M | -55.22M | -69.81M | -107.63M | -108.66M | -181.14M | -151.92M | -179.25M |
EBITDA Margin % | -183.87% | -68.66% | -712.28% | -405.68% | -387.02% | -3439.73% | -524.36% | -489556.76% | -178.29% | -203.13% |
EBITDA Growth % | - | 8.87% | -412.88% | -10.97% | -26.42% | -54.17% | -0.96% | -66.7% | 16.13% | 11.96% |
D&A (Non-Cash Add-back) | 626K | 697K | 1M | 1.44M | 1.52M | 2.4M | 4.2M | 6.71M | 7.63M | 301K |
EBIT | -11.27M | -10.4M | -45.63M | -56.66M | -71.33M | -110.03M | -112.87M | -187.84M | -159.55M | -179.55M |
Net Interest Income | 89K | 850K | 1.5M | 152K | 137K | 2.57M | 12.21M | 27.05M | 19.48M | 18.76M |
Interest Income | 89K | 850K | 1.5M | 152K | 137K | 2.57M | 12.21M | 27.05M | 19.48M | 18.76M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 49K | 848K | 1.46M | -29K | 16K | 2.54M | 12.03M | 26.97M | 19.44M | 18.65M |
Pretax Income | -11.22M▲ 0% | -9.55M▲ 14.9% | -49.31M▼ 416.2% | -56.69M▼ 15.0% | -71.32M▼ 25.8% | -107.49M▼ 50.7% | -100.84M▲ 6.2% | -160.87M▼ 59.5% | -140.11M▲ 12.9% | -160.9M▲ 0% |
Pretax Margin % | -193.83% | -67.59% | -705.78% | -416.49% | -395.37% | -3435.41% | -486.59% | -434778.38% | -164.43% | -182.34% |
Income Tax | -89K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.79% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -11.22M▲ 0% | -9.55M▲ 14.9% | -49.31M▼ 416.2% | -56.69M▼ 15.0% | -71.32M▼ 25.8% | -107.49M▼ 50.7% | -100.84M▲ 6.2% | -160.87M▼ 59.5% | -140.11M▲ 12.9% | -160.9M▲ 0% |
Net Margin % | -193.83% | -67.59% | -705.78% | -416.49% | -395.37% | -3435.41% | -486.59% | -434778.38% | -164.43% | -182.34% |
Net Income Growth % | - | 14.9% | -416.24% | -14.98% | -25.8% | -50.73% | 6.19% | -59.53% | 12.9% | 8.81% |
Net Income (Continuing) | -11.22M | -9.55M | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M | -140.11M | -160.9M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.76▲ 0% | -0.76▲ 0.0% | -2.00▼ 163.2% | -2.12▼ 6.0% | -2.46▼ 16.0% | -3.12▼ 26.8% | -2.58▲ 17.3% | -2.98▼ 15.5% | -2.42▲ 18.8% | -2.36▲ 0% |
EPS Growth % | - | 0% | -163.16% | -6% | -16.04% | -26.83% | 17.31% | -15.5% | 18.79% | 16.35% |
EPS (Basic) | -0.76 | -0.76 | -2.00 | -2.12 | -2.46 | -3.12 | -2.58 | -2.98 | -2.42 | - |
Diluted Shares Outstanding | 14.84M | 12.52M | 26.49M | 26.68M | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M | 68.06M |
Basic Shares Outstanding | 14.84M | 12.52M | 26.49M | 26.68M | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M | 68.06M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
FDMT Balance Sheet
4D Molecular Therapeutics, Inc. (FDMT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 24.5M | 94.07M | 52.51M | 282.66M | 256.28M | 220.51M | 296.59M | 434.93M | 413.13M | 405.36M |
Cash & Short-Term Investments | 23.85M | 91.76M | 49.65M | 276.73M | 247.78M | 213.55M | 288.23M | 424.88M | 402.65M | 390.89M |
Cash Only | 23.85M | 91.76M | 49.65M | 276.73M | 153M | 52.35M | 249.11M | 149.34M | 60.24M | 72.49M |
Short-Term Investments | 0 | 0 | 0 | 0 | 94.78M | 161.2M | 39.12M | 275.54M | 342.41M | 318.4M |
Accounts Receivable | 321K | 1.12M | 978K | 1.49M | 47K | 700K | 0 | 0 | 0 | 0 |
Days Sales Outstanding | 20.24 | 29.03 | 51.1 | 39.85 | 0.95 | 81.66 | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 4.44M | 0 | 6.26M | 8.36M | 10.05M | 10.48M | 14.47M |
Total Non-Current Assets | 2.82M | 2.9M | 5.73M | 5.67M | 97.21M | 41.34M | 43.3M | 125.45M | 153.58M | 107.54M |
Property, Plant & Equipment | 2.72M | 2.47M | 5.05M | 5.07M | 28.95M | 35.35M | 31.66M | 40.61M | 33.01M | 30.94M |
Fixed Asset Turnover | 2.13x | 5.72x | 1.38x | 2.68x | 0.62x | 0.09x | 0.65x | 0.00x | 2.58x | 2.59x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 67.65M | 4.91M | 10.95M | 80.58M | 0 | 302.35M |
Other Non-Current Assets | 105K | 429K | 677K | 602K | 602K | 1.08M | 684K | 4.26M | 120.57M | 76.6M |
Total Assets | 27.32M▲ 0% | 96.97M▲ 254.9% | 58.23M▼ 39.9% | 288.33M▲ 395.1% | 353.49M▲ 22.6% | 261.85M▼ 25.9% | 339.89M▲ 29.8% | 560.38M▲ 64.9% | 566.71M▲ 1.1% | 512.9M▲ 0% |
Asset Turnover | 0.21x | 0.15x | 0.12x | 0.05x | 0.05x | 0.01x | 0.06x | 0.00x | 0.15x | 0.18x |
Asset Growth % | - | 254.94% | -39.95% | 395.12% | 22.6% | -25.92% | 29.81% | 64.87% | 1.13% | -52.85% |
Total Current Liabilities | 5.91M | 8.05M | 12.96M | 16.74M | 16.34M | 15.73M | 18.95M | 29.15M | 43.98M | 43.4M |
Accounts Payable | 460K | 954K | 1.74M | 1.79M | 4.76M | 3.32M | 3.52M | 4.39M | 11.16M | 14.69M |
Days Payables Outstanding | 12.37 | 18.96 | 16.44 | 12.3 | 28.34 | 15.11 | 13.21 | - | 534.17 | 38.09 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 2.65M | 0 | 0 | 5.59M | 5.49M |
Deferred Revenue (Current) | 4.38M | 4.91M | 5.86M | 6.59M | 2.6M | 884K | 273K | 257K | 360K | 2.15M |
Other Current Liabilities | 279K | 0 | 0 | 0 | 0 | 3.18M | 3.87M | 0 | 26.87M | 22.87M |
Current Ratio | 4.15x | 11.68x | 4.05x | 16.88x | 15.69x | 14.02x | 15.65x | 14.92x | 9.39x | 9.34x |
Quick Ratio | 4.15x | 11.68x | 4.05x | 16.88x | 15.69x | 14.02x | 15.65x | 14.92x | 9.39x | 9.34x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 41M | 116.5M | 118.25M | 15.2M | 18.04M | 14.78M | 13.11M | 20.63M | 17.06M | 17.66M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.82M | 15.05M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 15.22M | 13.47M | 11.52M | 18.97M | 0 | 49.74M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 18.81M | 103.43M | 104.65M | 1.97M | 334K | 233K | 617K | 603K | 496K | 2.62M |
Total Liabilities | 46.91M | 124.56M | 131.2M | 31.94M | 34.38M | 30.51M | 32.06M | 49.78M | 61.05M | 61.07M |
Total Debt | 0 | 0 | 0 | 0 | 16.45M | 16.12M | 14.67M | 24.61M | 21.41M | 20.54M |
Net Debt | -23.85M | -91.76M | -49.65M | -276.73M | -136.55M | -36.23M | -234.44M | -124.73M | -38.83M | -51.95M |
Debt / Equity | - | - | - | - | 0.05x | 0.07x | 0.05x | 0.05x | 0.04x | 0.05x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.29x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | -19.59M▲ 0% | -27.59M▼ 40.8% | -72.97M▼ 164.5% | 256.39M▲ 451.4% | 319.11M▲ 24.5% | 231.34M▼ 27.5% | 307.83M▲ 33.1% | 510.61M▲ 65.9% | 505.66M▼ 1.0% | 451.84M▲ 0% |
Equity Growth % | - | -40.82% | -164.51% | 451.36% | 24.46% | -27.5% | 33.07% | 65.87% | -0.97% | -66.51% |
Book Value per Share | -1.32 | -2.20 | -2.75 | 9.61 | 11.51 | 7.15 | 7.87 | 9.47 | 8.73 | 6.64 |
Total Shareholders' Equity | -19.59M | -27.59M | -72.97M | 256.39M | 319.11M | 231.34M | 307.83M | 510.61M | 505.66M | 451.84M |
Common Stock | 1K | 1K | 1K | 3K | 3K | 3K | 4K | 5K | 6K | 5K |
Retained Earnings | -20.48M | -30.03M | -79.03M | -135.68M | -207M | -314.49M | -415.33M | -576.2M | -716.3M | -785.06M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -18.51M | -102.98M | -102.98M | -288.33M | -423K | -1.2M | 16K | 229K | 727K | -180K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FDMT Cash Flow Statement
4D Molecular Therapeutics, Inc. (FDMT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 8.24M | -16.25M | -36.71M | -50.91M | -69.13M | -86.69M | -75.79M | -134.59M | -109.08M | -129.45M |
Operating CF Margin % | 142.26% | -115.02% | -525.49% | -374% | -383.27% | -2770.37% | -365.74% | -363743.24% | -128.02% | - |
Operating CF Growth % | - | -297.3% | -125.89% | -38.68% | -35.8% | -25.39% | 12.57% | -77.57% | 18.95% | 17.97% |
Net Income | -11.22M | -9.55M | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M | -140.11M | -160.9M |
Depreciation & Amortization | 626K | 697K | 1M | 1.44M | 3.02M | 3.88M | 5.75M | 6.71M | 7.63M | 7.93M |
Stock-Based Compensation | 256K | 1.38M | 3.54M | 4.98M | 13.8M | 17.12M | 19.66M | 26.12M | 22.02M | 15.03M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 39K | 2K | 7.79M | 69K | 898K | 1.14M | -999K | -7.08M | -4.79M | -100K |
Working Capital Changes | 18.54M | -8.78M | 259K | -712K | -15.53M | -1.34M | 630K | 537K | 6.17M | 8.59M |
Change in Receivables | -320K | -803K | 146K | -508K | 1.44M | 47K | 0 | 0 | 0 | 0 |
Change in Inventory | -53K | 175K | 0 | 0 | -4.54M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -114K | 438K | 533K | 43K | 2.29M | -1.64M | 896K | 871K | 6.77M | 10.54M |
Cash from Investing | 7.67M | -414K | -3.2M | -1M | -172.68M | -17.05M | 115.72M | -302.44M | -92.97M | -56.03M |
Capital Expenditures | -573K | -414K | -3.2M | -1M | -9.11M | -11.54M | -2.77M | -3.79M | -536K | -672K |
CapEx % of Revenue | 9.9% | 2.93% | 45.85% | 7.35% | 50.5% | 368.68% | 13.37% | 10232.43% | 0.63% | 0.76% |
Acquisitions | 24K | 0 | 0 | 0 | 9.11M | 0 | 0 | 0 | 0 | 11K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 24K | 0 | 0 | 0 | -9.11M | 0 | 173.29M | 0 | 0 | 767K |
Cash from Financing | 16K | 84.58M | -2.19M | 278.98M | 118.09M | 3.08M | 156.83M | 337.25M | 112.96M | 124.44M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 16K | 0 | -2.19M | 278.13M | 114.3M | 3.08M | 148.34M | 331.41M | 112.96M | 124.33M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 84.58M | 0 | 857K | 3.79M | 0 | 8.49M | 5.84M | 0 | 116K |
Net Change in Cash | 15.93M▲ 0% | 67.91M▲ 326.4% | -42.11M▼ 162.0% | 227.07M▲ 639.3% | -123.72M▼ 154.5% | -100.65M▲ 18.7% | 196.76M▲ 295.5% | -99.77M▼ 150.7% | -89.09M▲ 10.7% | -68.48M▲ 0% |
Free Cash Flow | 7.66M▲ 0% | -16.67M▼ 317.5% | -39.91M▼ 139.5% | -51.91M▼ 30.1% | -78.24M▼ 50.7% | -98.22M▼ 25.5% | -78.56M▲ 20.0% | -138.37M▼ 76.1% | -109.08M▲ 21.2% | -130.06M▲ 0% |
FCF Margin % | 132.37% | -117.95% | -571.34% | -381.35% | -433.77% | -3139.05% | -379.11% | -373975.68% | -128.02% | -147.38% |
FCF Growth % | - | -317.46% | -139.49% | -30.05% | -50.73% | -25.53% | 20.01% | -76.13% | 21.17% | 17.14% |
FCF per Share | 0.52 | -1.33 | -1.51 | -1.95 | -2.82 | -3.04 | -2.01 | -2.57 | -1.88 | -1.91 |
FCF Conversion (FCF/Net Income) | -0.73x | 1.70x | 0.74x | 0.90x | 0.97x | 0.81x | 0.75x | 0.84x | 0.78x | 0.81x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FDMT Key Ratios
4D Molecular Therapeutics, Inc. (FDMT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -61.82% | -24.78% | -39.06% | -37.4% | -39.31% | -27.57% | -36.83% |
Return on Invested Capital (ROIC) | - | - | - | -65.96% | -43.7% | -63.05% | -61.35% | -28.07% | -34.17% |
Gross Margin | -29.95% | -454.22% | -289.64% | -240.17% | -2464.81% | -368.54% | 100% | 91.05% | -12.45% |
Net Margin | -67.59% | -705.78% | -416.49% | -395.37% | -3435.41% | -486.59% | -434778.38% | -164.43% | -182.34% |
Debt / Equity | - | - | - | 0.05x | 0.07x | 0.05x | 0.05x | 0.04x | 0.05x |
FCF Conversion | 1.70x | 0.74x | 0.90x | 0.97x | 0.81x | 0.75x | 0.84x | 0.78x | 0.81x |
Revenue Growth | 144.04% | -50.56% | 94.85% | 32.52% | -82.65% | 562.29% | -99.82% | 230194.59% | 383560.87% |
Related:FDMT Dividend History·FDMT Revenue History·FDMT Price History·FDMT P/E History·FDMT Financial Ratios·FDMT Institutional Holders
FDMT SEC Filings & Documents
4D Molecular Therapeutics, Inc. (FDMT) SEC filings — annual & quarterly reports (10-K, 10-Q)
FDMT Frequently Asked Questions
4D Molecular Therapeutics, Inc. (FDMT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
4D Molecular Therapeutics, Inc. (FDMT) reported $88.2M in revenue for fiscal year 2025. This represents a 1424% increase from $5.8M in 2017.
4D Molecular Therapeutics, Inc. (FDMT) grew revenue by 230194.6% over the past year. This is strong growth.
4D Molecular Therapeutics, Inc. (FDMT) reported a net loss of $160.9M for fiscal year 2025.
Dividend & Returns
4D Molecular Therapeutics, Inc. (FDMT) has a return on equity (ROE) of -27.6%. Negative ROE indicates the company is unprofitable.
4D Molecular Therapeutics, Inc. (FDMT) had negative free cash flow of $130.1M in fiscal year 2025, likely due to heavy capital investments.